Navigation Links
Mechanism for the in-vivo transport of siRNA
Date:9/22/2007

le of being bonded to other lipophilic substances in addition to cholesterol, and caused a reduction in the activity of a target gene in the liver at the same time. It turned out that there are several such fatty acids. But what is it in the blood to which all these RNAs conjugated with so-called lipophilic substances bond" The ETH Zurich researchers discovered that, depending on the fatty acid used, the binding partners are the well-known cholesterol transporters High Density Lipoproteins (HDL) and Low Density Lipoproteins (LDL) as well as the albumin (protein) present everywhere in the blood. Without these lipoprotein particles there is no uptake of siRNAs into the tissues, as became apparent from further experiments. In an additional experiment the scientists demonstrated that the uptake can be made considerably more efficient if the siRNA-fatty acid molecules are already firmly bonded to HDL and LDL before being administered. Stoffels team also discovered that there is preferential uptake into different tissues depending on whether an siRNA-fatty acid molecule is bonded to HDL or LDL: all LDL compounds trigger responses in the liver, but HDL compounds also do so in the intestine or kidneys.

An irritating finding

The latter finding indicated that the uptake proceeds via HDL and LDL receptors. The researchers proved this assumption by inactivating the receptors, with the result that uptake no longer occurred. Despite the clarity of the finding, it irritated Stoffel slightly. He found it hard to imagine that the siRNAs were able to enter the cell via the normal absorption route like HDL, because this route leads into the cells own digestive system with lysosomes that would degrade the siRNAs. So how would the siRNAs be able to avoid this degradation" Stoffel concluded that they simply use a different doorway into the cell. Thus the HDL and LDL receptors would only act as docking stations but not as an entry portal.

But what might t
'/>"/>

Contact: Professor Marcus Stoffel
41-446-334-560
Swiss Federal Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
2. Polymer Degradation Mechanisms Encountered in Pyrolysis-GC/MS
3. Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector?
4. Custom and library siRNA for efficient gene silencing
5. Custom and library siRNA for efficient gene silencing
6. Cancer siRNA Oligo Set Version 1.0
7. Library siRNA
8. Custom siRNA Oligo Synthesis Service
9. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
10. Quantification of siRNA Silencing Efficiency Using the LightCycler System
11. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... completion of a field clinical study of its canine osteoarthritis stem cell product, ... Aratana Therapeutics (Kansas City, KS) and will be marketed in the US by ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... and Promotion of OraQuick(R) HCV ... Test Outside the United States -, ... Corporation (NYSE: SGP ) and OraSure Technologies, Inc. (Nasdaq:,OSUR) ... of a rapid oral hepatitis C virus (HCV) test utilizing ...
... Sheets:,VXGN), WHAT: Jim Panek, CEO of VaxGen, and George Schreiner, CEO of ... oncology pipeline, discuss the status of the ... for the new Company., WHEN: 2:45 p.m. EST, Wednesday, February 13, 2008, ... VaxGen@BIOCEO, ...
... Feb. 8 Anesiva,Inc. (Nasdaq: ANSV ) announced ... board of directors. Mr. Janney previously served on Anesiva,s,board ... off,the board following the merger of Anesiva and AlgoRx ... Anesiva board of directors,and we are very pleased to ...
Cached Biology Technology:Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 2Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 3Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 4Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 5VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 2VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 3Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... , July 25, 2013 The following statement is being issued by ... regarding the Pacific Biosciences Securities Litigation SUPERIOR COURT OF THE ... MATEO IN RE PACIFIC BIOSCIENCES OF ... Case No. CIV509210 SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. ...
... , This news release is available in ... findings are reported in the current issue of the " Journal ... The body,s repair mechanisms begin to fail with increasing age. As ... for many diseases, including Alzheimer,s disease, diabetes, cardiovascular disorders and cancer, ...
... 25, 2013 Developing ways to treat cancer patients with drugs ... effects is one of the topics in the premiere segment ... the American Chemical Society (ACS), the world,s largest scientific society. ... on DVD . Titled Prized Science: ...
Cached Biology News:Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4Rapamycin: Limited anti-aging effects 2Rapamycin: Limited anti-aging effects 3American Chemical Society launches 2013 edition of popular Prized Science video series 2
Eliminate electrical interference from any analog signal, without filtering. Ideal for electrophysiology applications like EKG, EMG, and EEGs. Removes 50/60hz noise and harmonics caused by grounding ...
Buffer used for mitocapture assays....
... CyScribe GFX Purification Kit, 50 purifications. ... cDNA probesProvides efficient removal of unincorporated ... reactions with superior yields of labeled ... purification of cDNA labeled by either ...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: